Table 4 Post-PSM prognostic comparison of the different treatment regimens received by the enrolled patients within 4.5 h of stroke onset

CHADS2 score, M (IQR)

4.00 (3.00, 4.00)

3.00 (3.00, 4.00)

3.00 (3.00, 4.00)

4.00 (3.00, 4.00)

0.040^*

CHA2DS2-VASc score, M (IQR)

5.00 (4.00, 6.00)

5.00 (4.00, 5.75)

5.00 (4.00, 6.00)

5.00 (5.00, 6.00)

0.142

HAS-BLED score, M (IQR)

4.00 (3.00, 4.00)

3.00 (3.00, 4.00)

4.00 (3.00, 4.00)

4.00 (3.00, 4.00)

0.073

HAS-BLED score ≥ 3 points, n (%)

102 (89.5)

32 (84.2)

35 (92.1)

35 (92.1)

0.432

NIHSS score before treatment, score, M (IQR)

12.00 (7.25, 15.75)

11.00 (9.00, 13.75)

13.00 (9.00, 15.00)

13.00 (5.25, 16.00)

0.768

NIHSS score after 1-week treatment, M (IQR)

9.00 (2.25, 15.00)

6.50 (2.00, 12.50)

11.50 (4.00, 13.75)

10.50 (3.00, 15.00)

0.442

Reduction in NIHSS score, M (IQR)

1.00 (0.00, 5.00)

3.00 (1.00, 8.00)

1.00 (0.00, 5.00)

1.00 (0.00, 2.00)

0.025^**

Intracranial haemorrhage transformation, n (%)

11 (9.6)

6 (15.8)

2 (5.3)

3 (7.9)

0.281

Extracranial haemorrhage transformation, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1.000

Antiplatelet prophylaxis, n (%)

103 (90.4)

36 (94.7)

31 (81.6)

36 (94.7)

0.081

Insufficient to regulate secondary prevention, n (%)

101 (88.6)

33 (86.8)

31 (81.6)

37 (97.4)

0.078

3-month mRS, M (IQR)

3.08 (2.13)

2.92 (2.33)

2.97 (2.07)

3.34 (2.00)

0.647

Within 3-month mRS ≤ 2 points, n (%)

47 (41.2)

15 (39.5)

19 (50.0)

13 (34.2)

0.363

Death within 3 months, n (%)

23 (20.2)

9 (23.7)

8 (21.1)

6 (15.8)

0.683